GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.
Abstract
Obesity and diabetes are characterized by increased inflammation reflecting disordered control of innate immunity. We reveal a local intestinal intraepithelial lymphocyte (IEL)-GLP-1 receptor (GLP-1R) signaling network that controls mucosal immune responses. Glp1r expression was enriched in intestinal IEL preparations and copurified with markers of Tαβ and Tγδ IELs, the two main subsets of intestinal IELs. Exendin-4 increased cAMP accumulation in purified IELs and reduced the production of cytokines from activated IELs but not from splenocytes ex vivo. These actions were mimicked by forskolin, absent in IELs from Glp1r−/− mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action. Furthermore, Glp1r−/− mice exhibited dysregulated intestinal gene expression, an abnormal representation of microbial species in feces, and enhanced sensitivity to intestinal injury following administration of dextran sodium sulfate. Bone marrow transplantation using wild-type C57BL/6 donors normalized expression of multiple genes regulating immune function and epithelial integrity in Glp1r−/− recipient mice, whereas acute exendin-4 administration robustly induced the expression of genes encoding cytokines and chemokines in normal and injured intestine. Taken together, these findings define a local enteroendocrine-IEL axis linking energy availability, host microbial responses, and mucosal integrity to the control of innate immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the inflammatory environment, the M1 to M2 shift promoted by GLP-1 is crucial for reducing the expression of inflammatory factors such as IL-6, TNF-α, and iNOS.8,15,328”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [328]
In the citing paper
“Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“In the small intestine, intraepithelial lymphocytes (IELs) express high levels of Glp1r, triggering cAMP response upon activation by exendin-4 (33).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“Glp1r–/– mice exhibited exacerbated intestinal inflammation in a dextran sulfate sodium–induced model of colitis (33).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“Notably, GLP-1R expression in gut IELs is significantly lower in the colon than in the small intestine (33), suggesting that other cell types, such as enteric neurons (82), may contribute to the antiinflammatory actions of GLP-1 medicines in the colon.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 controls gut motility and food intake and stimulates insulin while simultaneously inhibiting glucagon secretion (4,5).”
BackgroundSelf-citationCani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518 · cited 1×
“Indeed, modulation (both gain and loss) of GLP-2R signaling robustly modifies gut barrier function and the extent of inflammation in murine models of diabetes characterized by gut injury and endotoxemia (46).”
BackgroundIntegrative analysis of environmental sequences using MEGAN4
Huson, D. H., Mitra, S., Ruscheweyh, H.-J., Weber, N., & Schuster, S. C. (2011) · Genome Research · doi:10.1101/gr.120618.111 · Cited by 1,541 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 9×
“Indeed, transient blockade of GLP-1 receptor (GLP-1R) signaling reduces insulin, increases glucagon, and impairs glucose tolerance in multiple species (4).”
BackgroundInfluentialSelf-citationEllingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2513 · Cited by 922 · cited 3×
“GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.”
BackgroundSelf-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialThe light and dark sides of intestinal intraepithelial lymphocytes
Cheroutre, H., Lambolez, F., & Mucida, D. (2011) · Nature Reviews Immunology · doi:10.1038/nri3007 · Cited by 693 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · cited 1×
“Proglucagon-producing L cells are among the most intensively studied enteroendocrine cells predominantly localized to the distal small bowel and colon (3).”
Background
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“The localization of GLP-1R expression to intestinal IELS within the immune system (Yusta et al., 2015) does not link direct activation of the immune GLP-1R to reduction of vascular or cardiac inflammation.”
BackgroundInfluentialSelf-citationCOVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citation
Metadata
- Authors
- Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., Sherman, P. M., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- Cell Biology Program, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
- McMaster University (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-03-03
- Volume
- 64
- Issue
- 7
- Pages
- 2537-2549
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1903699177
- Cited by
- 282
- References
- 56
- Citations by year
- 2026: 25 · 2025: 45 · 2024: 34 · 2023: 20 · 2022: 32 · 2021: 29 · 2020: 20 · 2019: 29 · 2018: 16 · 2017: 18 · 2016: 7 · 2015: 6
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Inc
- Canadian Institutes of Health Research (MOP 123391, Novo Nordisk Inc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- GLP-1 receptor agonists, exendin-4, exendin-9-39, intestinal intraepithelial lymphocytes, mucosal immunity, innate immunity, cAMP signaling, gut microbiota, intestinal injury, dextran sodium sulfate, bone marrow transplantation, obesity, cytokine and chemokine expression, epithelial barrier integrity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Female, Immunity, Innate, Intestinal Mucosa, Lymphocytes, Male, Mice, Inbred C57BL, Peptides, Venoms, Signal Transduction, Cytokines, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. https://app.cochat.ai/papers/10.2337/db14-1577
- The paper
- Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., Sherman, P. M., & Drucker, D. J. (2015). GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes. https://doi.org/10.2337/db14-1577
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.